- Home
- SILC vs ARMP Comparison
SILC vs ARMP Comparison
Compare SILC & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- ARMP
- Stock Information
- Founded
- SILC 1987
- ARMP N/A
- Country
- SILC Israel
- ARMP United States
- Employees
- SILC N/A
- ARMP N/A
- Industry
- SILC Computer Manufacturing
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- ARMP Health Care
- Exchange
- SILC Nasdaq
- ARMP Nasdaq
- Market Cap
- SILC 86.2M
- ARMP 92.4M
- IPO Year
- SILC 1994
- ARMP N/A
- Fundamental
- Price
- SILC $16.50
- ARMP $2.56
- Analyst Decision
- SILC Hold
- ARMP Strong Buy
- Analyst Count
- SILC 1
- ARMP 1
- Target Price
- SILC N/A
- ARMP $9.00
- AVG Volume (30 Days)
- SILC 20.3K
- ARMP 8.9K
- Earning Date
- SILC 07-31-2025
- ARMP 08-12-2025
- Dividend Yield
- SILC N/A
- ARMP N/A
- EPS Growth
- SILC N/A
- ARMP N/A
- EPS
- SILC N/A
- ARMP N/A
- Revenue
- SILC $58,651,000.00
- ARMP $6,868,000.00
- Revenue This Year
- SILC $6.53
- ARMP $8.43
- Revenue Next Year
- SILC $14.10
- ARMP N/A
- P/E Ratio
- SILC N/A
- ARMP N/A
- Revenue Growth
- SILC N/A
- ARMP 84.67
- 52 Week Low
- SILC $12.29
- ARMP $0.90
- 52 Week High
- SILC $18.61
- ARMP $2.96
- Technical
- Relative Strength Index (RSI)
- SILC 55.22
- ARMP 54.07
- Support Level
- SILC $15.03
- ARMP $2.44
- Resistance Level
- SILC $16.49
- ARMP $2.65
- Average True Range (ATR)
- SILC 0.61
- ARMP 0.16
- MACD
- SILC 0.02
- ARMP -0.01
- Stochastic Oscillator
- SILC 89.74
- ARMP 55.56
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.